A Study of ALT-836 in Combination With Gemcitabine for Locally Advanced or Metastatic Solid Tumors
Completed · Phase 1
Conditions studied: Locally Advanced Malignant Neoplasm, Malignant Solid Tumour
In brief
This is a Phase I, open-label, multi-center, competitive enrollment and dose-escalation study of ALT-836 in combination with standard of care gemcitabine in participants who have locally advanced or metastatic solid tumors. The purpose of this study is to determine the maximum tolerated dose (MTD), and to assess the safety and pharmacokinetic profile of ALT-836 given with gemcitabine. The clinical benefit, progression-free survival and overall survival of study participants will also be assessed.
Key facts
- Study ID
- NCT01325558
- Run by
- Altor BioScience
- People needed
- 30
- Starts
- 2011-05-01
- Expected to finish
- 2015-02-01
- Last updated by the study team
- 2016-07-15
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Emory University, Winship Cancer Institute — Atlanta, Georgia, United States
- University of Iowa Hospitals and Clinics — Iowa City, Iowa, United States
- University of Rochester Medical Center, James P. Wilmot Cancer Center — Rochester, New York, United States
- Carolinas Hematology-Oncology Associates — Charlotte, North Carolina, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.